C4 Therapeutics appoints Steve Fawell to board; Malcolm Salter retires after nearly a decade

C4 Therapeutics, Inc.

Malcolm Salter resigned from board effective August 29, 2024, after ~9 years; no disagreements.
Stephen Fawell, Ph.D. appointed as Class III director through 2026 annual meeting; granted 65,000 share options.
Fawell has 35 years drug discovery experience, most recently VP head of oncology small molecule discovery at AstraZeneca.
Ronald Cooper appointed chair of Nominating and Corporate Governance Committee; Bruce Downey added to Audit Committee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Malcolm Salter

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2024-08-29
Successor: Stephen Fawell
Filed: September 3, 2024, 7:59 PM ET

On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.

Appointed

Stephen Fawell

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2024-08-29
Filed: September 3, 2024, 7:59 PM ET

On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Malcolm Salter resigned as Director at C4 Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Fawell was appointed as Director at C4 Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-039023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.